VectivBio Holding AG (VECT) News
Filter VECT News Items
VECT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VECT News Highlights
- VECT's 30 day story count now stands at 3.
- Over the past 13 days, the trend for VECT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- AG, RARE and IRWD are the most mentioned tickers in articles about VECT.
Latest VECT News From Around the Web
Below are the latest news stories about VECTIVBIO HOLDING AG that investors may wish to consider to help them evaluate VECT as an investment opportunity.
Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio SharesBOSTON & BASEL, Switzerland, June 29, 2023--Ironwood Pharmaceuticals, Inc. ("Ironwood") (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG ("VectivBio") (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced the successful completion of the tender offer to purchase the outstanding ordinary shares of VectivBio (the "Shares") for $17.00 per share in cash (the |
VectivBio Extraordinary General Meeting of Shareholders Approved All ProposalsBASEL, Switzerland, June 26, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, announced that today's extraordinary general meeting approved each of the proposals of the Board of Directors, which satisfied one of the pending conditions to consummating the tender offer by Ironwood Pharmaceuticals, Inc. (“Ironwood”) to acquire all of |
Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBioBOSTON & BASEL, Switzerland, June 16, 2023--Ironwood Pharmaceuticals, Inc. ("Ironwood") (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG ("VectivBio") (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with Ironwood’s pending acqui |
Ironwood (IRWD) to Acquire VectivBio for $1B, Stock Up 3.6%Ironwood (IRWD) offers to acquire VectivBio, which will help strengthen its gastrointestinal treatment portfolio. |
Why Ironwood Pharmaceuticals Stock Bumped Higher TodayIronwood Pharmaceuticals (NASDAQ: IRWD) is choosing to go the acquisition route to grow its business. On Monday, the company announced it has agreed to acquire clinical-stage biotech VectivBio Holding (NASDAQ: VECT). Investors were clearly warm to that move, as they subsequently traded up Ironwood stock by almost 4% on the day. |
VectivBio Stock Catapults 39% After Ironwood Agrees To Buy It For $1 BillionIronwood Pharmaceuticals said Monday it will buy VectivBio for $1 billion. The deal sent VECT stock flying, while IRWD stock reversed higher. |
Ironwood spends $1B to acquire Swiss biotechIronwood Pharmaceuticals Inc. is beefing up its gastrointestinal drug portfolio by buying a Swiss biotech called VectivBio Holding AG. |
Why Shares of VectivBio Holding Are Up TodayShares of VectivBio Holdings (NASDAQ: VECT) were up more than 35% Monday morning after the clinical-stage biotech company received a buyout offer from Ironwood Pharmaceuticals (NASDAQ: IRWD). Ironwood's shares were down a little more than 2% on Monday morning. Ironwood, which specializes in gastrointestinal therapies, said it was acquiring VectivBio in a $1 billion all-cash deal, offering $17 a share for VectivBio, a 42% premium of what the stock closed at on Friday. |
Ironwood Pharmaceuticals to Buy VectivBio in $1 Billion Deal. The Sector Is Hot for M&A.The drugmaker is paying $17 a share for the Swiss biotech company. The move adds to the $71 billion worth of deals announced in the healthcare and life sciences space in the first quarter. |
Ironwood bulks up on digestive therapies with $1.15 billion VectivBio buy(Reuters) -Ironwood Pharmaceuticals Inc said on Monday it would buy Switzerland-based drug developer VectivBio Holding AG for $1.15 billion, adding a promising treatment for digestive disorders to its portfolio. Ironwood has offered $17 per share for VectivBio, a premium of about 43% to the stock's last close. VectivBio's shares were at $16.21 in morning trade, while Ironwood's stock fell 4.5% to $10. |